Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer

NCT02662062 is registered in ClinicalTrials.gov with Australian and New Zealand Urogenital and Prostate Cancer Trials Group as lead sponsor.

NCT NCT02662062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02662062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer
Lead sponsor
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase
Phase 2
Overall status
Completed
Start date
July 11, 2017
Completion date
August 26, 2024
Enrollment
28 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer